Buscar

Filtros actuales:
Comenzar nueva busqueda
Añadir filtros:

Usa los filtros para afinar la busqueda.


Resultados 21-30 de 59.
Resultados por ítem:
Vista previaFecha de publicaciónTítuloAutor(es)Acceso
2022 Health care use.pdf.jpg2022Healthcare use among people with diabetes mellitus in Europe: a population-based cross-sectional study
Fuentes-Merlos, Álvaro; Quesada-Rico, José Antonio; Reina, Raúl; Orozco-Beltrán, Domingo
2019 health care experience iexpac diabetes (1).pdf.jpg2020Healthcare experience among patients with type 2 diabetes: A cross-sectional survey using the IEXPAC tool
Orozco-Beltrán, Domingo; Artola-Menéndez, Sara; Hormigo-Pozo, Antonio; Cararach-Salami, Daniel; Alonso-Jerez, Juan Luis; Álvaro-Grande, Epifanio; Villabrille-Arias, Covadonga; de Toro-Santos8, Francisco Javier; Galindo-Puerto, María José; Marín-Jiménez, Ignacio; Gómez-García, Antón; Ledesma-Rodriguez, Rocío; Fernández, Gonzalo; Ferreira de Campos, Karine
2018 Calculating individualized (1) (1).pdf.jpg2017Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real‐ life clinical practice
Alvarez‐Guisasola, Fernando; Cebrián‐Cuenca, Ana M.; Cos, Xavier; Ruiz‐Quintero, Manuel; Millaruelo, Jose M.; Cahn, Avivit; Raz, Itamar; Orozco‐Beltrán, Domingo
Endocrine disruption in Crohn’s disease Bisphenol A enhances.pdf.jpg2021Endocrine disruption in Crohn’s disease: Bisphenol A enhances systemic inflammatory response in patients with gut barrier translocation of dysbiotic microbiota products
Linares, Raquel; Fernández, Mariana F.; Gutiérrez, Ana; García-Villalba, Rocío; Suárez, Beatriz; Martínez-Blázquez, José Alberto; Caparrós, Esther; Tomás-Barberán, Francisco A.; Francés, Rubén
Efficacy and safety of insulin glargine 300 UmL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2.pdf.jpg18-jul-2020Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial
Perez, Antonio; Carrasco-Sánchez, Francisco Javier; González, Carlos; Seguí-Ripoll, José Miguel; Trescolí, Carlos; Ena, Javier; Borrell, Mireia; Gomez Huelgas, Ricardo
Dysbiotic microbiota interactions in Crohn’s.pdf.jpg2021Dysbiotic microbiota interactions in Crohn’s disease
Caparrós, Esther; Wiest, Reiner; Scharl, Michael; Rogler, Gerhard; Gutiérrez Casbas, Ana; Yilmaz, Bahtiyar; Wawrzyniak, Marcin; Francés, Rubén
Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic.pdf.jpg2003Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia
Sanchez-Gonzalez, Blanca; Pascual-Ramirez, Jose C.; Fernandez Abellan, Pascual; Belinchón , Isabel ; Rivas, Concepción; Vegara-Aguilera, Gloria
Transcriptional regulation of chemokine network by biologic monotherapy.pdf.jpg2022Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s disease
Linares, Raquel; Gutiérrez, Ana; Márquez-Galera, Ángel; Caparrós, Esther; Aparicio, José R.; Madero, Lucía; Payá, Artemio; López-Atalaya, José P.; Francés, Rubén
Clinical Effects of Liraglutide in a Real-World Setting.pdf.jpg9-jun-2015Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
Mezquita-Raya, Pedro; Reyes-Garcia, Rebeca; Moreno-Perez, Oscar; Escalada-San Martin, Javier; Rubio Herrera, Miquel Ángel; Lopez de la Torre Casares, Martin
FXR-modulates the gut-vascular barrier by regulating.pdf.jpgdic-2019FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis
Sorribas, Marcel; Jakob, Manuel O.; Yilmaz, Bahtiyar; Li, Hai; Stuzt, David; Noser, Yannik; de Gottardi, Andrea; Moghadamrad, Sheida; Hassan, Moshin; Albillos, Agustin; Francés, Ruben; Juanola, Oriol; Spadoni, Ilaria; Rescigno, Maria; Wiest, Reiner